Revelation Biosciences, Inc. (NASDAQ:REVB) Shares Shorted: Short Interest Down 56.0% in September

Revelation Biosciences, Inc. (NASDAQ:REVB) was the target of a significant decrease in short interest in the month of September. As of September 15th, there was short interest totaling 256 shares, a decrease of 56.0% from the August 31st total of 582 shares. Based on an average daily volume of 14,833 shares, the short-interest ratio is presently 0.0 days. Currently, 0.0% of the company’s shares are sold short.

Revelation Biosciences Price Performance

Shares of REVB traded down $0.02 during midday trading on Monday, hitting $0.85. The stock had a trading volume of 33,088 shares, compared to its average volume of 252,186. The stock’s 50 day moving average is $1.03 and its 200 day moving average is $1.08. The firm has a market cap of $3.39 million, a PE ratio of -0.07 and a beta of -0.14. Revelation Biosciences has a 1 year low of $0.83 and a 1 year high of $6.76.

Revelation Biosciences (NASDAQ:REVB) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.87) EPS for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.01. As a group, equities research analysts expect that Revelation Biosciences will post -5.18 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, Weiss Ratings cut Revelation Biosciences from a “sell (e+)” rating to a “sell (e)” rating in a report on Tuesday, August 25th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, Revelation Biosciences currently has a consensus rating of “Sell”.

Institutional Inflows and Outflows

A hedge fund recently raised its position in Revelation Biosciences stock. Sabby Management LLC lifted its holdings in Revelation Biosciences, Inc. (NASDAQ:REVB) by 192.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 605,702 shares of the company’s stock after buying an additional 398,651 shares during the quarter. Revelation Biosciences makes up about 0.7% of Sabby Management LLC’s portfolio, making the stock its 8th biggest position. Sabby Management LLC owned 8.78% of Revelation Biosciences worth $484,000 as of its most recent SEC filing. 12.80% of the stock is currently owned by institutional investors.

Revelation Biosciences Company Profile

Revelation Biosciences, Inc is a clinical-stage biotechnology company focused on developing immunologic therapies for diseases with significant unmet medical needs. The company’s research is centered on therapeutics designed to stimulate or modulate the body’s innate immune system, the first line of defense against infection and other disease processes.

Its development pipeline has included REVTx-99, an investigational intranasal therapy based on a proprietary beta-glucan formulation. The candidate has been studied for its potential to help prevent or reduce the severity of respiratory viral infections and associated complications, including acute respiratory distress.